Abeona Therapeutics Inc. (0H7R.L)
USD 5.88
(-2.0%)
USD 5.88
(-2.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -10.07 Million USD | -45.37% |
| 2022 | -6.92 Million USD | 75.73% |
| 2021 | -28.55 Million USD | -638.71% |
| 2020 | -3.86 Million USD | 96.81% |
| 2019 | -121.3 Million USD | -546.98% |
| 2018 | -18.75 Million USD | 86.39% |
| 2017 | -137.75 Million USD | -99.23% |
| 2016 | -69.14 Million USD | -72.26% |
| 2015 | -40.13 Million USD | -260.95% |
| 2014 | -11.12 Million USD | -2522.64% |
| 2013 | -424 Thousand USD | -7.07% |
| 2012 | -396 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -11.59 Million USD | -319.97% |
| 2024 Q1 | 5.27 Million USD | 156.03% |
| 2023 Q3 | 642 Thousand USD | 209.0% |
| 2023 Q1 | 2.3 Million USD | 133.21% |
| 2023 FY | -9.41 Million USD | -35.84% |
| 2023 Q2 | -589 Thousand USD | -125.6% |
| 2023 Q4 | -9.41 Million USD | -1565.89% |
| 2022 Q1 | -17.12 Million USD | 40.03% |
| 2022 FY | -6.92 Million USD | 75.73% |
| 2022 Q4 | -6.92 Million USD | -149.48% |
| 2022 Q3 | -2.77 Million USD | 20.41% |
| 2022 Q2 | -3.48 Million USD | 79.62% |
| 2021 FY | -28.55 Million USD | -638.71% |
| 2021 Q1 | -5.79 Million USD | -3.93% |
| 2021 Q3 | -37.61 Million USD | -98.2% |
| 2021 Q4 | -28.55 Million USD | 24.1% |
| 2021 Q2 | -18.97 Million USD | -227.39% |
| 2020 Q1 | -34.14 Million USD | 72.24% |
| 2020 FY | -3.86 Million USD | 96.81% |
| 2020 Q2 | -7.01 Million USD | 79.45% |
| 2020 Q3 | -1.14 Million USD | 83.62% |
| 2020 Q4 | -5.57 Million USD | -385.47% |
| 2019 Q4 | -123 Million USD | -196.82% |
| 2019 FY | -121.3 Million USD | -546.98% |
| 2019 Q3 | -41.44 Million USD | -15.43% |
| 2019 Q2 | -35.9 Million USD | -88.98% |
| 2019 Q1 | -18.99 Million USD | -1.32% |
| 2018 Q2 | -49.99 Million USD | 62.13% |
| 2018 FY | -18.75 Million USD | 86.39% |
| 2018 Q1 | -131.99 Million USD | 4.18% |
| 2018 Q4 | -18.75 Million USD | 44.19% |
| 2018 Q3 | -33.59 Million USD | 32.79% |
| 2017 Q1 | -63.21 Million USD | 8.58% |
| 2017 FY | -137.75 Million USD | -99.23% |
| 2017 Q3 | -56.52 Million USD | 3.06% |
| 2017 Q4 | -137.75 Million USD | -143.71% |
| 2017 Q2 | -58.3 Million USD | 7.76% |
| 2016 Q2 | -34.3 Million USD | 8.27% |
| 2016 Q1 | -37.39 Million USD | 6.83% |
| 2016 FY | -69.14 Million USD | -72.26% |
| 2016 Q4 | -69.14 Million USD | -121.72% |
| 2016 Q3 | -31.18 Million USD | 9.09% |
| 2015 Q1 | -7.94 Million USD | 28.53% |
| 2015 FY | -40.13 Million USD | -260.95% |
| 2015 Q4 | -40.13 Million USD | 7.26% |
| 2015 Q3 | -43.28 Million USD | -42.33% |
| 2015 Q2 | -30.41 Million USD | -282.61% |
| 2014 Q1 | -299 Thousand USD | 29.48% |
| 2014 Q2 | -55 Thousand USD | 81.61% |
| 2014 Q3 | 85 Thousand USD | 254.55% |
| 2014 FY | -11.12 Million USD | -2522.64% |
| 2014 Q4 | -11.12 Million USD | -13182.35% |
| 2013 Q2 | -1.79 Million USD | -3496.0% |
| 2013 Q4 | -424 Thousand USD | 52.84% |
| 2013 Q1 | -50 Thousand USD | 87.37% |
| 2013 Q3 | -899 Thousand USD | 50.0% |
| 2013 FY | -424 Thousand USD | -7.07% |
| 2012 FY | -396 Thousand USD | 0.0% |
| 2012 Q4 | -396 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | -87.11 Million USD | 88.44% |
| Dynavax Technologies Corporation | 106.63 Million USD | 109.444% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 69.962% |
| Perrigo Company plc | 3.32 Billion USD | 100.303% |
| Illumina, Inc. | 1.21 Billion USD | 100.83% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 100.038% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 91.157% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 100.122% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 100.078% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 106.942% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 62.838% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 240.128% |
| Waters Corporation | 1.96 Billion USD | 100.514% |
| Biogen Inc. | 6.28 Billion USD | 100.16% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -41.845% |
| Evolus, Inc. | 63.7 Million USD | 115.808% |
| Adicet Bio, Inc. | -142 Million USD | 92.908% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -11.701% |
| bluebird bio, Inc. | 108.57 Million USD | 109.276% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 102.196% |
| FibroGen, Inc. | 56.76 Million USD | 117.741% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 100.88% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 244.531% |
| Homology Medicines, Inc. | 18.43 Million USD | 154.624% |
| Geron Corporation | 14.76 Million USD | 168.227% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 100.635% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 105.085% |
| Myriad Genetics, Inc. | 88.1 Million USD | 111.431% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 81.438% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 90.96% |
| Zoetis Inc. | 4.76 Billion USD | 100.211% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 100.48% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 102.659% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.895% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 30.888% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 100.955% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 131.585% |
| Verastem, Inc. | -37.27 Million USD | 72.984% |
| Nektar Therapeutics | 210.24 Million USD | 104.79% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 94.96% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 72.636% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 101.04% |
| OPKO Health, Inc. | 230.68 Million USD | 104.366% |
| Exelixis, Inc. | -73.05 Million USD | 86.214% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 105.68% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 92.562% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 93.332% |
| uniQure N.V. | -102.95 Million USD | 90.218% |
| Imunon, Inc. | -4.69 Million USD | -114.31% |
| Blueprint Medicines Corporation | 702.83 Million USD | 101.433% |
| Insmed Incorporated | 721.62 Million USD | 101.396% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 100.729% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 67.739% |
| TG Therapeutics, Inc. | 17.86 Million USD | 156.382% |
| Incyte Corporation | -3.17 Billion USD | 99.683% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 101.315% |